Drug reference
ceftaroline
Cephalosporin (Anti-MRSA) · Antibacterial, β-Lactam Antibiotic, Cell Wall Synthesis Inhibitor (Anti-MRSA Cephalosporin)
Cephalosporin (Anti-MRSA)Antibacterial, β-Lactam Antibiotic, Cell Wall Synthesis Inhibitor (Anti-MRSA Cephalosporin)
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
B
FDA category + note
Mechanism
Ceftaroline has structural modifications allowing for binding to and inactivation of the altered PBPs expressed by MRSA, MRSE, and penicillin-resistant S. pneumoniae. It has enhanced gram-positive activity, especially its ability to bind to the low-affinity PBPs.
Indications
Community-acquired pneumoniaSkin and soft-tissue infectionsNosocomial pneumoniasSkin and soft tissue infections (SSTIs)Invasive MRSA infections (with or without glycopeptides)Methicillin-resistant strains with intermediate or complete resistance to vancomycin (alone or in combination with daptomycin)Salvage therapy for persistent MRSA bacteremia (in combination with daptomycin or vancomycin)
Pharmacokinetics
Half-life
approximately 2 h
Protein binding
minimal (~20%)
Side effects
Common
Gastrointestinal side effects (e.g., diarrhea)
Serious
- Hypersensitivity reactions (rash to anaphylaxis)
- Neutropenia
- Serum sickness
- Stevens-Johnson syndrome
- Nephropathy
- Neurotoxicity (seizure, high doses, renal impairment)
Pregnancy & lactation
Pregnancy
B
Related guidelines
Community-acquired pneumonia
ICMR · Pulmonology · 2022
Community-acquired pneumonia
IDSA · Pulmonology · 2019
Skin and soft tissue infections
IDSA · Infectious Diseases · 2010
Antimicrobial resistance — clinical roadmap
MOHFW · Infectious Diseases · 2012
Drug-resistant tuberculosis
RNTCP · Pulmonology · 2025
Ask House about ceftaroline
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e·Verified: 2026-05-10 · House clinical team